Lim, Zi Yi <br/><br/>
Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.  [electronic resource] 

 -  British journal of haematology  Aug 2007 
 - 517-26 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0007-1048 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2007.06676.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Alemtuzumab<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Hematopoietic Stem Cell Transplantation<br/>Histocompatibility Testing<br/>Humans<br/>Leukemia, Myeloid, Acute--mortality<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--mortality<br/>Prospective Studies<br/>Time Factors<br/>Transplantation Chimera<br/>Transplantation Conditioning--methods<br/>Transplantation, Homologous<br/>Treatment Outcome